← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Charlesson, Llp
Oklahoma City, OK
$11,261,641
Total funding
23
Grants
Funding over time
peak $2.1M · FY2005–16$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$11,261,641 · 23
By mechanism
R44$6,373,932 · 4
R43$4,887,709 · 19
Investigators at Charlesson, Llp
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Safety and Toxicology Studies of CLT-005 as a Therapeutic for Diabetic Macular Ed$1,095,787
R44 · FY2011 · EY
Safety and Toxicology Studies of CLT-005 as a Therapeutic for Diabetic Macular Ed$873,711
R44 · FY2012 · EY
Developing A Novel Therapy for Diabetic Retinopathy$785,308
R44 · FY2015 · EY
Sustained delivery of linomide-5 for diabetic retinopathy and macular degeneratio$729,032
R44 · FY2008 · EY
Developing A Novel Therapy for Diabetic Retinopathy$710,237
R44 · FY2016 · EY
Safety and Toxicology Studies of CLT-005 as a Therapeutic for Diabetic Macular Ed$680,041
R44 · FY2013 · EY
Sustained delivery of linomide-5 for diabetic retinopathy and macular degeneratio$659,645
R44 · FY2009 · EY
Nanotechnology for Treatment of Diabetic Retinopathy$570,438
R43 · FY2008 · EY
Nanotechnology for Treatment of Diabetic Retinopathy$570,438
R43 · FY2007 · EY
A Novel Thalidomide Analog for the Treatment of Diabetic Macular Edema$449,845
R44 · FY2007 · EY
A Novel Thalidomide Analog for the Treatment of Diabetic Macular Edema$390,326
R44 · FY2008 · EY
Novel emulsion-based formulation of the anti-glaucoma MSH-1001 for improved topic$287,947
R43 · FY2011 · EY
Multitargeted Therapy for Age-related Macular Degeneration$265,992
R43 · FY2011 · EY
Novel Linomide Analog for Treatment of Diabetic Retinopathy$248,294
R43 · FY2006 · EY
Novel Antioxidants for Treatment of Diabetic Retinopathy$248,094
R43 · FY2009 · EY
Developing A Novel Therapy for Diabetic Retinopathy$246,418
R43 · FY2013 · EY
A novel Stat3 inhibitor for treating retinal inflammation and neovascularization$241,279
R43 · FY2008 · EY
Novel Combretastatin A4 analogs for Treatment of Retinal Neovascularization$237,429
R43 · FY2007 · EY
A Small Molecule Targeting Wnt Pathway for Treatment of Diabetic Retinopathy$231,087
R43 · FY2012 · EY
Development of a novel anti-inflammatory treatment for clinical management of end$227,286
R43 · FY2009 · EY